Markets

Amgen: Biotech Promise

Shares of the world's largest biotech company should perform well in 2006, says one analyst.

Growing sales for its existing blockbusters combined with a promising pipeline of potential drugs should lead to standout performance for shares of Amgen (AMGN) in 2006, according to Citigroup analyst Elise Wang. "In our opinion, Amgen remains one of the most attractive large-cap health care growth stories," she says.

The stock is included on Citigroup's recently published list of top picks for the coming year.

Unlike large drugmakers, which excel at selling mass-market medicines for common ailments, biotech firms focus on unmet needs. Amgen's products treat illnesses such as anemia, rheumatoid arthritis and an immune-system condition in chemotherapy patients. Wang notes that Amgen has five multibillion-dollar drugs currently on the market, and it's hoping to expand some of these drugs for additional uses.

In late December, Amgen announced a $2.2-billion deal to acquire Abgenix, with whom it has been partnering to develop a potential new cancer therapy called panitumumab. "Amgen believes [panitumumab] could reach peak sales of $2 billion worldwide," Wang says. Also in Amgen's pipeline is a drug called denosumab (to treat osteoporosis and other conditions) as well as another cancer drug. Wang expects to hear more about the progress of these drugs in the months ahead.

In addition to its sales growth and product pipeline, Amgen sports a healthy balance sheet -- particularly notable in an industry where many companies are striving to turn a profit. That financial strength makes the stock all the more appealing in Wang's view.

Earnings increased 21% annually over the past five years, and analysts estimate 15% annual profit growth over the long term. Plus, Morningstar analyst Karen Andersen points out that Amgen generates ample cash, which it uses for acquisitions and for its aggressive share-repurchase program.

Despite Amgen's financial health, however, the potential for a trip-up remains. For example, analysts acknowledge that the shares could be hurt should the company have problems with a key drug in its pipeline.

At $79, the stock sells for 22 times the 2006 consensus earnings estimate of $3.64 per share. That's a higher price-earnings ratio than that of the SP 500 but compares with a P/E of 51 for rival Genentech. Wang figures Amgen's stock can reach $100 over the next year.

--Lisa Dixon

Most Popular

Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
The 10 Best Closed-End Funds (CEFs) for 2022
CEFs

The 10 Best Closed-End Funds (CEFs) for 2022

These high-yielding CEFs won't just significantly boost your portfolio income. They'll also allow you to buy their underlying stocks and bonds at a di…
January 12, 2022
Sweet Silicon: 5 Superb Semiconductor Stocks for 2022
stocks

Sweet Silicon: 5 Superb Semiconductor Stocks for 2022

If 2021 was a good year for the chip industry, 2022 could be downright great. Here are five semiconductor stocks if you're seeking out growth.
January 11, 2022

Recommended

Stock Market Today (1/26/22): Powell Rate Comments Rupture Morning Rally
Stock Market Today

Stock Market Today (1/26/22): Powell Rate Comments Rupture Morning Rally

The market didn't flinch at the Fed's nod toward a March rate hike, but stocks swooned after Chair Powell said there's "quite a bit of room to raise i…
January 26, 2022
Stock Market Today (1/25/22): Stocks End Down on Another Roller-Coaster Day
Stock Market Today

Stock Market Today (1/25/22): Stocks End Down on Another Roller-Coaster Day

The major indexes stage another comeback Tuesday but this time can't escape declines; Microsoft falls after hours despite an earnings beat.
January 25, 2022
Could the Stock Market Crash for Real? Here’s How to Prepare
investing

Could the Stock Market Crash for Real? Here’s How to Prepare

After a long march to record heights, the stock market tripped into correction territory in January. How should you react? Thoughtfully.
January 25, 2022
The 60/40 Portfolio Is Dead. Long Live 33/33/33.
investing

The 60/40 Portfolio Is Dead. Long Live 33/33/33.

A portfolio of stocks and bonds used to be the gold standard, but it just doesn’t cut it anymore. It’s time to throw some alternative investments into…
January 25, 2022